GlassScriptPhysician profile
Peter G Hasapis
NPI 1720154354
$1,813.17
in general payments reported to CMS, 2019-2025
31 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $97.54 · 2023: $385 · 2024: $375 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.19 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $287.40 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $197.24 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $147.16 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $126.38 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.04 | 2019-2023 | Jardiance |
| Kaleo, INC. | $104.75 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $102.05 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Pfizer INC. | $71.41 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $68.04 | 2025 | Rexulti |
| Baxter Healthcare | $50.17 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Janssen Biotech, INC. | $44.43 | 2019 | |
| Lilly USA, LLC | $43.02 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $42.35 | 2023 | |
| Amgen INC. | $41.56 | 2024-2025 | Otezla, Repatha, Repatha |
| Sanofi Pasteur INC. | $39.08 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38.69 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $38.40 | 2019-2020 | |
| Tris Pharma INC | $29.15 | 2019-2024 | Dyanavel Xr |
| Corcept Therapeutics | $23.91 | 2024 | Korlym |
| Dermira, INC. | $23.04 | 2019 | |
| Sumitomo Pharma America, INC. | $22.49 | 2025 | Gemtesa |
| Ironshore Pharmaceuticals INC. | $21.70 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.30 | 2024 | Eliquis |
| Intra-Sana Laboratories | $19.23 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Kowa Pharmaceuticals America, INC. | $17.94 | 2025 | Zoryve |
| Genentech USA, INC. | $17.78 | 2019 | |
| Amarin Pharma, INC. | $16.12 | 2020 | |
| Cranial Technologies, INC | $15.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.10 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $13.72 | 2019 | |
| Neos Therapeutics, LP | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hasapis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.